AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$2.25 USD
-0.31 (-12.11%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $2.28 +0.03 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
AEON Biopharma, Inc. [AEON]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: AEON Biopharma, Inc.
Industry: Unclassified
Saving Costs And Seeking Funding To Support Program Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: AEON Biopharma, Inc.
Industry: Unclassified
Awaiting Announcement Of Next Steps; Lower PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: AEON Biopharma, Inc.
Industry: Unclassified
Sideswiped by Another High Placebo Rate Obscures the Path Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: AEON Biopharma, Inc.
Industry: Unclassified
Alignment With FDA Charts Path Forward in Chronic and Episodic Migraine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: AEON Biopharma, Inc.
Industry: Unclassified
ABP-450 Shows Impressive Effect in Treating Episodic Migraine
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: AEON Biopharma, Inc.
Industry: Unclassified
Aeon Looks Poised to Disrupt the Blockbuster Neurotoxin Market; Initiate at Buy With $18 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
|